Citations

Clear

5 citation(s) found for "Chan, Kok Hoe".

SGLT2 inhibitor use and long-term outcomes in anthracycline-treated breast cancer: A real-world retrospective cohort study.
Ng, Lay She , Ng, Wern Lynn , Lin, Yone Phar , Chan, Kok Hoe, Advani, Pooja

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e12707 Get It

e12707 Background: Anthracycline-based chemotherapy remains a cornerstone of breast cancer treatment but is limited by dose-dependent cardiotoxicity. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated cardioprotective effects across diverse populations. Preclinical models suggest they may mitigate anthracycline-induced cardiotoxicity. However, clinical data evaluating this association remain limited. Methods: We conducted a retrospective cohort study using the TriNetX real world data platform, including adults with breast cancer who received anthracycline within one year of diagnosis. Patients were stratified by SGLT2i use within one year of diagnosis into the SGLT2i group and the non-SGLT2i group. Propensity score matching (PSM) was performed to balance baseline demographics and comorbidities. Outcomes included 3-year all-cause mortality, heart failure, myocardial infarction, atrial fibrillation, mean left ventricular ejection fraction (LVEF), mean Troponin I, and mean brain natriuretic peptide level (BNP), analyzed using risk ratios (RR) and Kaplan-Meier survival analysis. Results: After PSM, 2912 patients were included in each group, with a mean follow-up of 630.3 days in SGLT2i group and 756.7 days in non-SGLT2i group. Mean age was 61.5 years vs 62.3 years (SGLT2i group vs non-SGLT2i group), with more than 98% of females in both groups. Most patients were White (49.0% in SGLT2i group and 48.6% in non-SGLT2i group), followed by African American (23.7% vs. 23.4%), unknown races (14.0% vs 14.0%), and Asian (9.5% vs. 9.8%). At baseline, the SGLT2i group had lower mean LVEF (53.4% vs 61.9%), higher mean Troponin I (0.992 vs 0.0849), and higher mean BNP levels (778 vs 240). SGLT2i group was associated with significantly lower 3-year all-cause mortality (Hazard ratio 0.52, 95% CI 0.44–0.61). Heart failure incidence (9.5% vs 6.0%; p = 0.0005) was significantly higher in the SGLT2i group. Mean LVEF in SGLT2i group was significantly lower (51.7% vs 58.9; p < 0.0001) and mean BNP level was significantly higher in SGLT2i group (685.5 vs 383.0; p = 0.0336). No significant differences were observed in myocardial infarction (3.9% vs 3.4%; p = 0.4459), atrial fibrillation (3.4% vs 4.5%; p = 0.0799), and mean troponin I (0.085 vs 0.113, p = 0.5191). Conclusions: In this real-world cohort, SGLT2i use was associated with lower 3-year all-cause mortality despite higher rates of heart failure. Notably, patients receiving SGLT2i had worse baseline cardiac function yet demonstrated more favorable trends in cardiac biomarkers, including smaller declines in LVEF, reductions in BNP, and lower mean troponin I levels, suggesting a slower progression of cardiac dysfunction. These findings support a potential cardioprotective and survival benefit of SGLT2i in patients with breast cancer receiving anthracycline therapy and warrant confirmation in future studies.
Glucagon-like peptide-1 receptor agonist use in lung cancer patients receiving immune checkpoint inhibitors: A real-world study.
Ng, Wern Lynn , Ng, Lay She , Lin, Yone Phar , Chan, Kok Hoe, Zhao, Yujie, Chan, Kok Hoe

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 8598-8598

10.1200/jco.2026.44.16_suppl.8598 Get It

8598 Background: Immune checkpoint inhibitors (ICI) have become a cornerstone of treatment for lung cancer. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have been associated with improved outcomes in cancer patients in prior studies; however, their impact on outcomes among lung cancer patients receiving immunotherapy remains limited. Methods: We conducted a retrospective cohort study using the TriNetX real-world data platform. Adult patients with lung cancer treated with ICIs, including PD-1, PD-L1, or CTLA-4 inhibitors, were included. Patients were stratified based on exposure to GLP-1 RA. Propensity score matching (1:1) was performed to balance baseline demographics and comorbidities, including type 2 diabetes mellitus and body mass index. Primary outcomes included all-cause mortality, intensive care unit (ICU) admission, and hospitalization. Secondary outcomes included immune-related pneumonitis, colitis/enteritis, cachexia, and major adverse cardiovascular events (MACE). Results: After matching, 2,013 patients were included in each group, with a median follow-up of 372 days in the GLP-1 RA group and 383 days in the non-GLP-1 RA group. Mean age was 66.8 and 67.2 years, respectively, and approximately 50% of patients were male. Most patients were White (77.2% vs 71.8%), followed by Black (14.1% vs 14.0%) and Asian (2.1% vs 1.8%). GLP-1 RA use was associated with a significantly lower all-cause mortality rate compared with non-use (35.7% vs. 53.4%; p < 0.0001), with a hazard ratio of 0.65 (95% CI, 0.59–0.71). Significant reductions were also observed in ICU admissions (22.8% vs 29.0%; p = 0.0001), hospitalizations (64.1% vs 71.8%; p = 0.0001), pneumonitis (5.2% vs 6.8%; p = 0.0457), and MACE (19.9% vs 25.3%; p = 0.0026). No significant differences were observed in colitis/enteritis (9.3% vs 9.4%; p = 0.9704) or cachexia (8.0% vs 9.8%; p = 0.0650). In a subgroup analysis of lung cancer patients not receiving ICI, GLP-1 RA use was similarly associated with lower mortality, ICU admission, hospitalization, and MACE, without differences in immune-related toxicities. Conclusions: GLP-1 RA use among lung cancer patients was associated with improved survival, reduced healthcare utilization, and fewer selected adverse events in patients receiving ICI therapy. These associations likely reflect established metabolic and cardiovascular benefits of GLP-1 RA and may also involve antitumor mechanisms suggested in prior studies. Residual confounding related to healthcare access and socioeconomic factors cannot be fully excluded and should be considered when interpreting these findings. Prospective studies are warranted to validate these observations and clarify underlying biological mechanisms.
SGLT2 inhibitors and cardiovascular outcomes in patients with multiple myeloma and concomitant type 2 diabetes mellitus
Tan, Jia Yi , Vignarajah, Aravinthan , Yeo, Yong Hao , Chisti, Mohammad Muhsin , Hilal, Talal , Chan, Kok Hoe , Chisti, Mohammad Muhsin , Hilal, Talal , Yeo, Yong Hao , Chan, Kok Hoe

Mayo Clinic

Leukemia & Lymphoma | July 22, 2025 | Volume: 66 | Issue: 12 | Pages: 2320-2323

10.1080/10428194.2025.2536681 | PMID 40694617 Get It

Impact of SGLT2 inhibitors in patients with multiple myeloma and diabetes mellitus.
Tan, Jia Yi , Vignarajah, Aravinthan , Yeo, Yong Hao , Chan, Kok Hoe , Chisti, Mohammad Muhsin , Hilal, Talal

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e19515 Get It

e19515 Background: The prevalence of diabetes mellitus (DM) is significantly higher in patients with multiple myeloma (MM) compared to the general population. DM has been associated with worse outcomes in MM, including reduced overall survival and increased mortality. The impact of diabetes in patients with MM is further compounded by cardiotoxicity from proteasome inhibitors and the increased thromboembolic risk linked to immunomodulatory agents. Given the potential benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors, we hypothesized that their use in MM patients with DM could improve clinical outcomes and mitigate adverse events in this population. Methods: We utilized the TriNetX network to identify patients (≥18 years old) with MM and DM between January 1, 2013, and January 1, 2019. We categorized the patients into SGLT2 inhibitors users and SGLT2 inhibitors users. Inclusion in the SGLT2 inhibitors group required exposure to SGLT2 inhibitors for at least 1 year. 1:1 Propensity score matching was performed to match these two groups based on comorbidities, medications, baseline hemoglobin A1c, low-density lipoprotein, and left ventricular ejection fraction to produce two comparable cohorts. The study outcomes include all-cause mortality, all-cause hospitalization, acute venous thromboembolism (VTE), acute heart failure (HF), acute myocardial infarction (MI), cardiac arrhythmia, and cardiac arrest over the 5-year follow-up duration. Results: A total of 43,078 patients were identified, including 3,640 SGLT2 inhibitors users and 39,438 non-SGLT-2 inhibitors users. After 1:1 propensity-score matching, there were 3,379 SGLT-2 inhibitor users (68.9 ± 10.3 years of age, 38.0% female, 23.9% African American [AA]) and 3,379 non-SGLT-2 inhibitor users (68.9 ± 11.0 years of age, 35.9% female, 22.2% AA). SGLT-2 inhibitors users were associated with lower rates of all-cause mortality (odds ratio [OR]: 0.34, 95% confidence interval [CI]: 0.30-0.39) and all-cause hospitalization (OR: 0.52, 95% CI: 0.47-0.58). Lower odds of acute VTE (OR: 0.59, 95% CI: 0.49-0.70), acute HF (OR: 0.89, 95% CI: 0.81-0.98), acute MI (OR: 0.81, 95% CI: 0.69-0.95), cardiac arrhythmia (OR: 0.82, 95% CI: 0.70-0.97), and cardiac arrest (OR: 0.57, 95% CI: 0.44-0.74) were reported among SGLT-2 inhibitors users compared to non-SGLT2 inhibitor users. Conclusions: Our study revealed that only 8.4% of patients with DM and MM were prescribed an SGLT-2 inhibitor. Our study also demonstrated that SGLT2 inhibitor use was associated with lower odds of all-cause mortality and hospitalization, reduced risk of VTE, and favorable cardiovascular outcomes in this patient population.
A Review of the Current Approach and Treatment Landscape for Stage III Non-Small Cell Lung Cancer
Sridhar, Arthi , Khan, Hina, Yohannan, Binoy , Kataria, Nilansh, Jafri, Syed Hasan, Chan, Kok Hoe , Yohannan, Binoy , Chan, Kok Hoe

Mayo Clinic

Journal of Clinical Medicine | April 30, 2024 | Volume: 13 | Issue: 9 | Pages: 2633

10.3390/jcm13092633 | PMID 38731161 Get It

The therapeutic landscape of the management of stage III non-small cell lung cancer (NSCLC) has drastically evolved with the incorporation of immunotherapy and targeted therapy. Stage III NSCLC accounts for one-third of the cases and the treatment strategy of these locally advanced presentations are diverse, ranging from surgical to non-surgical options; with the incorporation of chemo-immunotherapy, radiation, and targeted therapies wherever applicable. The staging of this disease has also changed, and it is essential to have a strong multidisciplinary approach to do justice to patient care. In this article, we aim to navigate the nuanced approaches in the diagnosis and treatment of stage III NSCLC and expand on the evolution of the management of this disease.